(CNBS) Amplify Seymour Cannabis - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US0321088546 • Miscellaneous Sector

CNBS: Cannabis, Hemp, Securities, Derivatives, Ecosystem

The Amplify Seymour Cannabis ETF (NYSE ARCA: CNBS) is a targeted exchange-traded fund designed to provide exposure to U.S. companies operating in the cannabis and hemp industries. Under normal market conditions, the fund invests at least 80% of its net assets in securities of U.S. firms that generate 50% or more of their revenue from the cannabis and hemp ecosystem. This includes direct industry participants and companies providing goods and services to the sector. The fund may also invest in derivatives that economically resemble direct holdings in these securities.

As a non-diversified fund, CNBS can allocate a greater proportion of its assets to a smaller number of holdings, which may amplify exposure to sector-specific risks and opportunities. The fund is managed by Amplify Investments LLC, which employs an active approach to select companies poised to benefit from the growth and evolution of the U.S. cannabis and hemp markets.

Ticker Symbol: CNBS Exchange: NYSE ARCA Type: ETF Country Origin: USA ETF Category: Miscellaneous Sector

Based on the provided data, CNBS is currently trading at $19.33, below its 20-day and 50-day moving averages of $20.92 and $21.98, respectively. The 200-day moving average stands at $31.65, indicating a downtrend over the past year. The funds average trading volume over the past 20 days is approximately 50,415 shares, with an average true range (ATR) of 0.71, suggesting moderate volatility. CNBS has total assets under management (AUM) of $68.88 million, reflecting its niche focus within the cannabis sector.

Over the next three months, CNBS is likely to remain sensitive to broader market trends and sector-specific developments. The funds price could face headwinds if the 20-day and 50-day moving averages continue to decline below the 200-day moving average, signaling bearish momentum. However, any positive regulatory developments or revenue growth in the cannabis sector could act as catalysts for upside. The ATR of 0.71 suggests that price fluctuations may remain contained, but investors should monitor macroeconomic conditions and industry news closely.

Additional Sources for CNBS ETF

CNBS ETF Overview

Market Cap in USD 69m
Category Miscellaneous Sector
TER 0.75%
IPO / Inception 2019-07-15

CNBS ETF Ratings

Growth 5y -84.3%
Fundamental -
Dividend 72.5%
Rel. Strength Industry -55.6
Analysts -
Fair Price Momentum 14.59 USD
Fair Price DCF -

CNBS Dividends

Dividend Yield 12m 40.87%
Yield on Cost 5y 14.91%
Annual Growth 5y 154.18%
Payout Consistency 42.9%

CNBS Growth Ratios

Growth Correlation 3m -87.3%
Growth Correlation 12m -91.2%
Growth Correlation 5y -83%
CAGR 5y -23.70%
CAGR/Max DD 5y -0.25
Sharpe Ratio 12m -1.12
Alpha -57.04
Beta 0.35
Volatility 74.88%
Current Volume 8.3k
Average Volume 20d 4.7k
What is the price of CNBS stocks?
As of March 09, 2025, the stock is trading at USD 18.56 with a total of 8,280 shares traded.
Over the past week, the price has changed by -5.56%, over one month by -16.42%, over three months by -27.62% and over the past year by -49.69%.
Is Amplify Seymour Cannabis a good stock to buy?
No, based on ValueRay Analyses, Amplify Seymour Cannabis (NYSE ARCA:CNBS) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -84.33 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CNBS as of March 2025 is 14.59. This means that CNBS is currently overvalued and has a potential downside of -21.39%.
Is CNBS a buy, sell or hold?
Amplify Seymour Cannabis has no consensus analysts rating.
What are the forecast for CNBS stock price target?
According to ValueRays Forecast Model, CNBS Amplify Seymour Cannabis will be worth about 16.1 in March 2026. The stock is currently trading at 18.56. This means that the stock has a potential downside of -13.09%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 16.1 -13.1%